Yseop’s Post

View organization page for Yseop

11,363 followers

3d Edited

Emmanuel Walckenaer, CEO of Yseop, returns to AI Uncovered to discuss AI’s impact on regulatory submissions, clinical workflows and medical writing as adoption accelerates in 2025. He and Tim Martin explore 2024’s biggest breakthroughs, the role of automation and key priorities for a successful future. A must-listen! Tune in now: 👉Yseop page: https://bit.ly/4b5Jckp 👉Youtube: https://bit.ly/4hIwNFC 👉Soundcloud: https://bit.ly/41pjXGD 👉 Amazon: https://bit.ly/3D2z6Ed 👉 Spotify: https://bit.ly/41pflQL 👉 Apple: https://bit.ly/43618JO #AI #Automation #TechPodcast #LLM #GenerativeAI #ChatGPT #Pharma #Biopharma #ArtificialIntelligence #LifeSciences #MedicalWriting #RegulatoryAffairs #Biotech #ClinicalTrials #Regulatory #AIUncovered #AIinPharma #PharmaInnovation #genai

Transcript

We see an incredible number of summers, you know, the top 26 to 100 top 100, you know, smaller companies having one drug every year, 1 drug every two years in the market, super invested in super interesting. So you you can see super rapidly in the market is expanding now and my my, you know, if you need a prediction, I would say, all right, that's a by the end of 2026, I think 50% five zero. Of of the top 100 companies will have deployed and will be in production with these type of technology in in two years.

To view or add a comment, sign in

Yseop

11,363 followers

View Profile Connect

More from this author

Explore topics